NL-OMON21077已完成不适用
A randomised sequential trial of LithiumIn amyotrophic lateral sclerosis
Prof.dr L.H. van den Berg, neurologist in the University Hospital of Utrecht0 个研究点目标入组 191 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 191
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Definite, probable, or probable-laboratory supported ALS according to the revised El Escorial World Federation of Neurology criteria.
- •2. Intake of riluzole 2dd 50 mg
排除标准
- •1. Tracheostomy, tracheostomal ventilation of any type, non-invasive ventilation more than 16 hours/ day, or supplemental oxygen during the last three months prior to inclusion.
- •2. Any medical condition or intoxication known to have an association with motor neuron dysfunction, which might confound or obscure the diagnosis of ALS.
研究者
相似试验
尚未招募
不适用
ithium trial bij ALSALSamyotrophic lateral sclerosisamyotrofische laterale scleroseNL-OMON20046Prof. dr. L.H. van den Berg, neurologist Dep. neurology, UMC-UtrechtHeidelberglaan 100/HP G03.2283584CX UtrechtTel: +31-88-7557939Fax: +31-30-2542100Email: L.H.vandenBerg@umcutrecht.nl191
进行中（未招募）
不适用
A randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALSAmyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS can occur at anytime in adulthood. Muscle weakness gradually progresses. Approximately 50% of patients die within 3 years after onset of symptoms, usually as the result of respiratory failure. To date, only one drug, i.e. riluzole, has proven to extend survival in patients with ALS, but only by approximately 3 to 6 months.MedDRA version: 9.1Level: LLTClassification code 10052889Term: ALSEUCTR2008-002110-22-NLProf. dr L.H. van den Berg, UMC-Utrecht
招募中
2 期
A randomised sequential trial of Lithium in amyotrophic lateral sclerosismotor neuron diseaseamyotrophic lateral sclerosis (ALS)10029317NL-OMON31977niversitair Medisch Centrum Utrecht191
已完成
2 期
Safety and Tolerability of Lithium in Spinocerebellar Ataxia 2 (SCA2)SPINOCEREBELLAR ATAXIA 2NCT00998634Federico II University20
终止
2 期
Lithium in Multiple System AtrophyMultiple System AtrophyNCT00997672Federico II University10